Quantitative proteomic analysis of patients’ plasma revealed a possible role for the HGF-MET pathway in LDN-dependent resistance to anti-PD-1 therapy, suggesting the combination of MET inhibitors, known agents in cancer therapy, with anti-PD-1/PD-L1 therapy as an alternative approach [83,296]. Here, MET is linked to cancer.